schliessen

Filtern

 

Bibliotheken

Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants

Summary Background Identification of mechanisms that limit poliovirus replication is crucial for informing decisions aimed at global polio eradication. Studies of mucosal immunity induced by oral poliovirus (OPV) or inactivated poliovirus (IPV) vaccines and mixed schedules thereof will determine the... Full description

Journal Title: The Lancet Infectious Diseases 2016, Vol.16 (12), p.1377-1384
Main Author: Wright, Peter F, Prof
Other Authors: Connor, Ruth I, PhD , Wieland-Alter, Wendy F, MS , Hoen, Anne G, PhD , Boesch, Austin W, MS , Ackerman, Margaret E, PhD , Oberste, M Steven, PhD , Gast, Chris, PhD , Brickley, Elizabeth B, PhD , Asturias, Edwin J, MD , Rüttimann, Ricardo, MD , Bandyopadhyay, Ananda S, MPH
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: United States: Elsevier Ltd
ID: ISSN: 1473-3099
Link: https://www.ncbi.nlm.nih.gov/pubmed/27638357
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5611465
title: Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants
format: Article
creator:
  • Wright, Peter F, Prof
  • Connor, Ruth I, PhD
  • Wieland-Alter, Wendy F, MS
  • Hoen, Anne G, PhD
  • Boesch, Austin W, MS
  • Ackerman, Margaret E, PhD
  • Oberste, M Steven, PhD
  • Gast, Chris, PhD
  • Brickley, Elizabeth B, PhD
  • Asturias, Edwin J, MD
  • Rüttimann, Ricardo, MD
  • Bandyopadhyay, Ananda S, MPH
subjects:
  • Analysis
  • Antibodies, Neutralizing - immunology
  • Antibodies, Viral - blood
  • Articles
  • Clinical trials
  • Disease control
  • Disease prevention
  • Drug Therapy, Combination
  • Enterovirus
  • Epidemiology
  • Feces - virology
  • Humans
  • Immunity, Mucosal - immunology
  • Immunization Schedule
  • Immunoglobulin A
  • Immunoglobulin G
  • Infants
  • Infections
  • Infectious Disease
  • Infectious Diseases
  • Latin America
  • Medical colleges
  • Mucous membrane
  • Picornaviridae
  • Poliomyelitis
  • Poliomyelitis - immunology
  • Poliomyelitis - prevention & control
  • Poliovirus
  • Poliovirus - immunology
  • Poliovirus - isolation & purification
  • Poliovirus Vaccines - immunology
  • Respiratory syncytial virus
  • Serogroup
  • Studies
  • Vaccination
  • Vaccines
  • Virus Shedding - immunology
ispartof: The Lancet Infectious Diseases, 2016, Vol.16 (12), p.1377-1384
description: Summary Background Identification of mechanisms that limit poliovirus replication is crucial for informing decisions aimed at global polio eradication. Studies of mucosal immunity induced by oral poliovirus (OPV) or inactivated poliovirus (IPV) vaccines and mixed schedules thereof will determine the effectiveness of different vaccine strategies to block virus shedding. We used samples from a clinical trial of different vaccination schedules to measure intestinal immunity as judged by neutralisation of virus and virus-specific IgA in stools. Methods In the FIDEC trial, Latin American infants were randomly assigned to nine groups to assess the efficacy of two schedules of bivalent OPV (bOPV) and IPV and challenge with monovalent type 2 OPV, and stools samples were collected. We selected three groups of particular interest—the bOPV control group (serotypes 1 and 3 at 6, 10, and 14 weeks), the trivalent attenuated OPV (tOPV) control group (tOPV at 6, 10, and 14 weeks), and the bOPV–IPV group (bOPV at 6, 10, and 14 weeks plus IPV at 14 weeks). Neutralising activity and poliovirus type-specific IgA were measured in stool after a monovalent OPV type 2 challenge at 18 weeks of age. Mucosal immunity was measured by in-vitro neutralisation of a type 2 polio pseudovirus (PV2). Neutralisation titres and total and poliovirus-type-specific IgG and IgA concentrations in stools were assessed in samples collected before challenge and 2 weeks after challenge from all participants. Findings 210 infants from Guatemala and Dominican Republic were included in this analysis. Of 38 infants tested for mucosal antibody in the tOPV group, two were shedding virus 1 week after challenge, compared with 59 of 85 infants receiving bOPV (p
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 1473-3099
fulltext: fulltext
issn:
  • 1473-3099
  • 1474-4457
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.582313
LOCALfalse
PrimoNMBib
record
control
sourceidgale_pubme
recordidTN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5611465
sourceformatXML
sourcesystemPC
galeidA521978544
sourcerecordidA521978544
originalsourceidFETCH-LOGICAL-1909t-c70df02990b4ebcfafb96da0941433bae0523ca7e904fd5926b9f708280e0a713
addsrcrecordideNqNk9tu1DAURSMEoqXwCaBIvBSpKXbiXAxSUVVxkyp44PJqOc7x1MWxBzspmo_gnzmZlDJTVbSKlDj2Pisn9t5J8pSSQ0po9fILZXWRFYTzfVq9KHCKZ-xesovTLGOsrO-vx7NkJ3kU4zkhtKaEPUx28roqmqKsd5Pf36VSxkFmXDcq6NJ-VD5Km5q-H50ZVung06W3xl-YMMZXqXTSrqKJqdep8mc-DDHVwfe4kPoluMzKFuxBGqTrfG8iIpV3Q_DW4nAIZmK79FQOeD_uIRiFlcZp6Yb4OHmgpY3w5PK5l3x79_bryYfs9PP7jyfHpxnlhA-ZqkmnSc45aRm0Skvd8qqThDPKiqKVQMq8ULIGTpjuSp5XLdc1afKGAJE1LfaSo5m7HNseOgXYoLRiGUwvw0p4acT2ijNnYuEvRFlRyqoSAZ9mwPTL0gTYqu0cDKKDblyKX1rgtgveFFCVJedd3tBWF7plkjZNyzuiaccAgfuXHQX_c4Q4CNw7BdZKB36MgjYlzeuCkfoOUlaxnOQ5R-nza9JzPwY8wbWK1lXNsLMr1UJaEHgUHv9ZTVBxXOaU103J2H9VDH1FG9x_VB3eoMKrg96gEUAbnN_C3qlg8wvPbigQm8QbBZuEgw1BO0b0f8RbNIuzIS7kGON2h3eQb9LLWa6CjzGAvrIGJWKKrlhHV0y5FPi2jq7YaHt23lXV36yi4PU1sDIDxmhKlzT2VvybuRowVxcGgojKgMPIo3sV2tWbWwlH1wjKGofxtT9gBfGfs0TMBZkhE4NWawIr_gB543XI
sourcetypeOpen Access Repository
isCDItrue
recordtypearticle
pqid1841767498
display
typearticle
titleVaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants
sourceAlma/SFX Local Collection
creatorWright, Peter F, Prof ; Connor, Ruth I, PhD ; Wieland-Alter, Wendy F, MS ; Hoen, Anne G, PhD ; Boesch, Austin W, MS ; Ackerman, Margaret E, PhD ; Oberste, M Steven, PhD ; Gast, Chris, PhD ; Brickley, Elizabeth B, PhD ; Asturias, Edwin J, MD ; Rüttimann, Ricardo, MD ; Bandyopadhyay, Ananda S, MPH
creatorcontribWright, Peter F, Prof ; Connor, Ruth I, PhD ; Wieland-Alter, Wendy F, MS ; Hoen, Anne G, PhD ; Boesch, Austin W, MS ; Ackerman, Margaret E, PhD ; Oberste, M Steven, PhD ; Gast, Chris, PhD ; Brickley, Elizabeth B, PhD ; Asturias, Edwin J, MD ; Rüttimann, Ricardo, MD ; Bandyopadhyay, Ananda S, MPH
descriptionSummary Background Identification of mechanisms that limit poliovirus replication is crucial for informing decisions aimed at global polio eradication. Studies of mucosal immunity induced by oral poliovirus (OPV) or inactivated poliovirus (IPV) vaccines and mixed schedules thereof will determine the effectiveness of different vaccine strategies to block virus shedding. We used samples from a clinical trial of different vaccination schedules to measure intestinal immunity as judged by neutralisation of virus and virus-specific IgA in stools. Methods In the FIDEC trial, Latin American infants were randomly assigned to nine groups to assess the efficacy of two schedules of bivalent OPV (bOPV) and IPV and challenge with monovalent type 2 OPV, and stools samples were collected. We selected three groups of particular interest—the bOPV control group (serotypes 1 and 3 at 6, 10, and 14 weeks), the trivalent attenuated OPV (tOPV) control group (tOPV at 6, 10, and 14 weeks), and the bOPV–IPV group (bOPV at 6, 10, and 14 weeks plus IPV at 14 weeks). Neutralising activity and poliovirus type-specific IgA were measured in stool after a monovalent OPV type 2 challenge at 18 weeks of age. Mucosal immunity was measured by in-vitro neutralisation of a type 2 polio pseudovirus (PV2). Neutralisation titres and total and poliovirus-type-specific IgG and IgA concentrations in stools were assessed in samples collected before challenge and 2 weeks after challenge from all participants. Findings 210 infants from Guatemala and Dominican Republic were included in this analysis. Of 38 infants tested for mucosal antibody in the tOPV group, two were shedding virus 1 week after challenge, compared with 59 of 85 infants receiving bOPV (p<0·0001) and 53 of 87 infants receiving bOPV–IPV (p<0·0001). Mucosal type 2 neutralisation and type-specific IgA were noted primarily in response to tOPV. An inverse correlation was noted between virus shedding and both serum type 2 neutralisation at challenge (p<0·0001) and mucosal type 2 neutralisation at challenge (p<0·0001). Interpretation Mucosal type-2-specific antibodies can be measured in stool and develop in response to receipt of OPV type 2 either in the primary vaccine series or at challenge. These mucosal antibodies influence the amount of virus that is shed in an established infection. Funding Bill & Melinda Gates Foundation.
identifier
0ISSN: 1473-3099
1EISSN: 1474-4457
2DOI: 10.1016/S1473-3099(16)30169-4
3PMID: 27638357
4CODEN: LANCAO
languageeng
publisherUnited States: Elsevier Ltd
subjectAnalysis ; Antibodies, Neutralizing - immunology ; Antibodies, Viral - blood ; Articles ; Clinical trials ; Disease control ; Disease prevention ; Drug Therapy, Combination ; Enterovirus ; Epidemiology ; Feces - virology ; Humans ; Immunity, Mucosal - immunology ; Immunization Schedule ; Immunoglobulin A ; Immunoglobulin G ; Infants ; Infections ; Infectious Disease ; Infectious Diseases ; Latin America ; Medical colleges ; Mucous membrane ; Picornaviridae ; Poliomyelitis ; Poliomyelitis - immunology ; Poliomyelitis - prevention & control ; Poliovirus ; Poliovirus - immunology ; Poliovirus - isolation & purification ; Poliovirus Vaccines - immunology ; Respiratory syncytial virus ; Serogroup ; Studies ; Vaccination ; Vaccines ; Virus Shedding - immunology
ispartofThe Lancet Infectious Diseases, 2016, Vol.16 (12), p.1377-1384
rights
0The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license
12016 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license
2Copyright © 2016 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license. Published by Elsevier Ltd.. All rights reserved.
3COPYRIGHT 2016 Elsevier B.V.
4Copyright Elsevier Limited Dec 01, 2016
52016 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license 2016
lds50peer_reviewed
oafree_for_read
citedbyFETCH-LOGICAL-1909t-c70df02990b4ebcfafb96da0941433bae0523ca7e904fd5926b9f708280e0a713
citesFETCH-LOGICAL-1909t-c70df02990b4ebcfafb96da0941433bae0523ca7e904fd5926b9f708280e0a713
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27638357$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Wright, Peter F, Prof
1Connor, Ruth I, PhD
2Wieland-Alter, Wendy F, MS
3Hoen, Anne G, PhD
4Boesch, Austin W, MS
5Ackerman, Margaret E, PhD
6Oberste, M Steven, PhD
7Gast, Chris, PhD
8Brickley, Elizabeth B, PhD
9Asturias, Edwin J, MD
10Rüttimann, Ricardo, MD
11Bandyopadhyay, Ananda S, MPH
title
0Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants
1The Lancet Infectious Diseases
addtitleLancet Infect Dis
descriptionSummary Background Identification of mechanisms that limit poliovirus replication is crucial for informing decisions aimed at global polio eradication. Studies of mucosal immunity induced by oral poliovirus (OPV) or inactivated poliovirus (IPV) vaccines and mixed schedules thereof will determine the effectiveness of different vaccine strategies to block virus shedding. We used samples from a clinical trial of different vaccination schedules to measure intestinal immunity as judged by neutralisation of virus and virus-specific IgA in stools. Methods In the FIDEC trial, Latin American infants were randomly assigned to nine groups to assess the efficacy of two schedules of bivalent OPV (bOPV) and IPV and challenge with monovalent type 2 OPV, and stools samples were collected. We selected three groups of particular interest—the bOPV control group (serotypes 1 and 3 at 6, 10, and 14 weeks), the trivalent attenuated OPV (tOPV) control group (tOPV at 6, 10, and 14 weeks), and the bOPV–IPV group (bOPV at 6, 10, and 14 weeks plus IPV at 14 weeks). Neutralising activity and poliovirus type-specific IgA were measured in stool after a monovalent OPV type 2 challenge at 18 weeks of age. Mucosal immunity was measured by in-vitro neutralisation of a type 2 polio pseudovirus (PV2). Neutralisation titres and total and poliovirus-type-specific IgG and IgA concentrations in stools were assessed in samples collected before challenge and 2 weeks after challenge from all participants. Findings 210 infants from Guatemala and Dominican Republic were included in this analysis. Of 38 infants tested for mucosal antibody in the tOPV group, two were shedding virus 1 week after challenge, compared with 59 of 85 infants receiving bOPV (p<0·0001) and 53 of 87 infants receiving bOPV–IPV (p<0·0001). Mucosal type 2 neutralisation and type-specific IgA were noted primarily in response to tOPV. An inverse correlation was noted between virus shedding and both serum type 2 neutralisation at challenge (p<0·0001) and mucosal type 2 neutralisation at challenge (p<0·0001). Interpretation Mucosal type-2-specific antibodies can be measured in stool and develop in response to receipt of OPV type 2 either in the primary vaccine series or at challenge. These mucosal antibodies influence the amount of virus that is shed in an established infection. Funding Bill & Melinda Gates Foundation.
subject
0Analysis
1Antibodies, Neutralizing - immunology
2Antibodies, Viral - blood
3Articles
4Clinical trials
5Disease control
6Disease prevention
7Drug Therapy, Combination
8Enterovirus
9Epidemiology
10Feces - virology
11Humans
12Immunity, Mucosal - immunology
13Immunization Schedule
14Immunoglobulin A
15Immunoglobulin G
16Infants
17Infections
18Infectious Disease
19Infectious Diseases
20Latin America
21Medical colleges
22Mucous membrane
23Picornaviridae
24Poliomyelitis
25Poliomyelitis - immunology
26Poliomyelitis - prevention & control
27Poliovirus
28Poliovirus - immunology
29Poliovirus - isolation & purification
30Poliovirus Vaccines - immunology
31Respiratory syncytial virus
32Serogroup
33Studies
34Vaccination
35Vaccines
36Virus Shedding - immunology
issn
01473-3099
11474-4457
fulltexttrue
rsrctypearticle
creationdate2016
recordtypearticle
recordideNqNk9tu1DAURSMEoqXwCaBIvBSpKXbiXAxSUVVxkyp44PJqOc7x1MWxBzspmo_gnzmZlDJTVbSKlDj2Pisn9t5J8pSSQ0po9fILZXWRFYTzfVq9KHCKZ-xesovTLGOsrO-vx7NkJ3kU4zkhtKaEPUx28roqmqKsd5Pf36VSxkFmXDcq6NJ-VD5Km5q-H50ZVung06W3xl-YMMZXqXTSrqKJqdep8mc-DDHVwfe4kPoluMzKFuxBGqTrfG8iIpV3Q_DW4nAIZmK79FQOeD_uIRiFlcZp6Yb4OHmgpY3w5PK5l3x79_bryYfs9PP7jyfHpxnlhA-ZqkmnSc45aRm0Skvd8qqThDPKiqKVQMq8ULIGTpjuSp5XLdc1afKGAJE1LfaSo5m7HNseOgXYoLRiGUwvw0p4acT2ijNnYuEvRFlRyqoSAZ9mwPTL0gTYqu0cDKKDblyKX1rgtgveFFCVJedd3tBWF7plkjZNyzuiaccAgfuXHQX_c4Q4CNw7BdZKB36MgjYlzeuCkfoOUlaxnOQ5R-nza9JzPwY8wbWK1lXNsLMr1UJaEHgUHv9ZTVBxXOaU103J2H9VDH1FG9x_VB3eoMKrg96gEUAbnN_C3qlg8wvPbigQm8QbBZuEgw1BO0b0f8RbNIuzIS7kGON2h3eQb9LLWa6CjzGAvrIGJWKKrlhHV0y5FPi2jq7YaHt23lXV36yi4PU1sDIDxmhKlzT2VvybuRowVxcGgojKgMPIo3sV2tWbWwlH1wjKGofxtT9gBfGfs0TMBZkhE4NWawIr_gB543XI
startdate2016
enddate2016
creator
0Wright, Peter F, Prof
1Connor, Ruth I, PhD
2Wieland-Alter, Wendy F, MS
3Hoen, Anne G, PhD
4Boesch, Austin W, MS
5Ackerman, Margaret E, PhD
6Oberste, M Steven, PhD
7Gast, Chris, PhD
8Brickley, Elizabeth B, PhD
9Asturias, Edwin J, MD
10Rüttimann, Ricardo, MD
11Bandyopadhyay, Ananda S, MPH
general
0Elsevier Ltd
1Elsevier B.V
2Elsevier Limited
3Elsevier BV
4Elsevier Science ;, The Lancet Pub. Group
scope
06I.
1AAFTH
2CGR
3CUY
4CVF
5ECM
6EIF
7NPM
8AAYXX
9CITATION
10BKMMT
11BSHEE
120TZ
133V.
147QL
157RV
167U9
177X7
187XB
1988E
208AO
218C1
228C2
238FI
248FJ
258FK
26ABUWG
27BENPR
28C1K
29FYUFA
30GHDGH
31H94
32K9.
33KB0
34M0S
35M1P
36M7N
37NAPCQ
38PQEST
39PQQKQ
40PQUKI
417X8
42BOBZL
43CLFQK
445PM
sort
creationdate2016
titleVaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants
authorWright, Peter F, Prof ; Connor, Ruth I, PhD ; Wieland-Alter, Wendy F, MS ; Hoen, Anne G, PhD ; Boesch, Austin W, MS ; Ackerman, Margaret E, PhD ; Oberste, M Steven, PhD ; Gast, Chris, PhD ; Brickley, Elizabeth B, PhD ; Asturias, Edwin J, MD ; Rüttimann, Ricardo, MD ; Bandyopadhyay, Ananda S, MPH
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1909t-c70df02990b4ebcfafb96da0941433bae0523ca7e904fd5926b9f708280e0a713
rsrctypearticles
prefilterarticles
languageeng
creationdate2016
topic
0Analysis
1Antibodies, Neutralizing - immunology
2Antibodies, Viral - blood
3Articles
4Clinical trials
5Disease control
6Disease prevention
7Drug Therapy, Combination
8Enterovirus
9Epidemiology
10Feces - virology
11Humans
12Immunity, Mucosal - immunology
13Immunization Schedule
14Immunoglobulin A
15Immunoglobulin G
16Infants
17Infections
18Infectious Disease
19Infectious Diseases
20Latin America
21Medical colleges
22Mucous membrane
23Picornaviridae
24Poliomyelitis
25Poliomyelitis - immunology
26Poliomyelitis - prevention & control
27Poliovirus
28Poliovirus - immunology
29Poliovirus - isolation & purification
30Poliovirus Vaccines - immunology
31Respiratory syncytial virus
32Serogroup
33Studies
34Vaccination
35Vaccines
36Virus Shedding - immunology
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Wright, Peter F, Prof
1Connor, Ruth I, PhD
2Wieland-Alter, Wendy F, MS
3Hoen, Anne G, PhD
4Boesch, Austin W, MS
5Ackerman, Margaret E, PhD
6Oberste, M Steven, PhD
7Gast, Chris, PhD
8Brickley, Elizabeth B, PhD
9Asturias, Edwin J, MD
10Rüttimann, Ricardo, MD
11Bandyopadhyay, Ananda S, MPH
collection
0ScienceDirect Open Access Titles
1Elsevier:ScienceDirect:Open Access
2Medline
3MEDLINE
4MEDLINE (Ovid)
5MEDLINE
6MEDLINE
7PubMed
8CrossRef
9Gale General OneFile (A&I only)
10Academic OneFile (A&I only)
11Pharma and Biotech Premium PRO
12ProQuest Central (Corporate)
13Bacteriology Abstracts (Microbiology B)
14Nursing & Allied Health Database
15Virology and AIDS Abstracts
16Health & Medical Collection
17ProQuest Central (purchase pre-March 2016)
18Medical Database (Alumni Edition)
19ProQuest Pharma Collection
20Public Health Database
21Lancet Titles
22Hospital Premium Collection
23Hospital Premium Collection (Alumni Edition)
24ProQuest Central (Alumni) (purchase pre-March 2016)
25ProQuest Central (Alumni Edition)
26ProQuest Central
27Environmental Sciences and Pollution Management
28Health Research Premium Collection
29Health Research Premium Collection (Alumni)
30AIDS and Cancer Research Abstracts
31ProQuest Health & Medical Complete (Alumni)
32Nursing & Allied Health Database (Alumni Edition)
33Health & Medical Collection (Alumni Edition)
34Medical Database
35Algology Mycology and Protozoology Abstracts (Microbiology C)
36Nursing & Allied Health Premium
37ProQuest One Academic Eastern Edition
38ProQuest One Academic
39ProQuest One Academic UKI Edition
40MEDLINE - Academic
41OpenAIRE (Open Access)
42OpenAIRE
43PubMed Central (Full Participant titles)
jtitleThe Lancet Infectious Diseases
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Wright, Peter F, Prof
1Connor, Ruth I, PhD
2Wieland-Alter, Wendy F, MS
3Hoen, Anne G, PhD
4Boesch, Austin W, MS
5Ackerman, Margaret E, PhD
6Oberste, M Steven, PhD
7Gast, Chris, PhD
8Brickley, Elizabeth B, PhD
9Asturias, Edwin J, MD
10Rüttimann, Ricardo, MD
11Bandyopadhyay, Ananda S, MPH
formatjournal
genrearticle
ristypeJOUR
atitleVaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants
jtitleThe Lancet Infectious Diseases
addtitleLancet Infect Dis
date2016
risdate2016
volume16
issue12
spage1377
epage1384
pages1377-1384
issn1473-3099
eissn1474-4457
codenLANCAO
abstractSummary Background Identification of mechanisms that limit poliovirus replication is crucial for informing decisions aimed at global polio eradication. Studies of mucosal immunity induced by oral poliovirus (OPV) or inactivated poliovirus (IPV) vaccines and mixed schedules thereof will determine the effectiveness of different vaccine strategies to block virus shedding. We used samples from a clinical trial of different vaccination schedules to measure intestinal immunity as judged by neutralisation of virus and virus-specific IgA in stools. Methods In the FIDEC trial, Latin American infants were randomly assigned to nine groups to assess the efficacy of two schedules of bivalent OPV (bOPV) and IPV and challenge with monovalent type 2 OPV, and stools samples were collected. We selected three groups of particular interest—the bOPV control group (serotypes 1 and 3 at 6, 10, and 14 weeks), the trivalent attenuated OPV (tOPV) control group (tOPV at 6, 10, and 14 weeks), and the bOPV–IPV group (bOPV at 6, 10, and 14 weeks plus IPV at 14 weeks). Neutralising activity and poliovirus type-specific IgA were measured in stool after a monovalent OPV type 2 challenge at 18 weeks of age. Mucosal immunity was measured by in-vitro neutralisation of a type 2 polio pseudovirus (PV2). Neutralisation titres and total and poliovirus-type-specific IgG and IgA concentrations in stools were assessed in samples collected before challenge and 2 weeks after challenge from all participants. Findings 210 infants from Guatemala and Dominican Republic were included in this analysis. Of 38 infants tested for mucosal antibody in the tOPV group, two were shedding virus 1 week after challenge, compared with 59 of 85 infants receiving bOPV (p<0·0001) and 53 of 87 infants receiving bOPV–IPV (p<0·0001). Mucosal type 2 neutralisation and type-specific IgA were noted primarily in response to tOPV. An inverse correlation was noted between virus shedding and both serum type 2 neutralisation at challenge (p<0·0001) and mucosal type 2 neutralisation at challenge (p<0·0001). Interpretation Mucosal type-2-specific antibodies can be measured in stool and develop in response to receipt of OPV type 2 either in the primary vaccine series or at challenge. These mucosal antibodies influence the amount of virus that is shed in an established infection. Funding Bill & Melinda Gates Foundation.
copUnited States
pubElsevier Ltd
pmid27638357
doi10.1016/S1473-3099(16)30169-4
oafree_for_read